Contrarian Sales Techniques

DECEMBER 4, 2023

Imagine this: a pharmaceutical sales representative, armed with the latest and greatest in medical advancements, sets out to make their mark in the competitive healthcare industry. Compromising on quality might save a few bucks initially but can lead to a tattered, unprofessional look that does more harm than good in the long run.

Sales 52

Sales Pharmaceutical Sales Pharma Ethics 52

Salesforce

SEPTEMBER 16, 2022

What do trusted healthcare organizations do differently? We asked 12,000 healthcare consumers about their experiences, relationships and interactions with their health and healthcare providers, and learned how big an impact trust has on health outcomes. Better segmentation leads to more relevant and actionable engagement.

Patients 52

Patients Healthcare Healthcare Food 52

pharmaphorum

DECEMBER 18, 2022

However, most models are based on an old-fashioned and expensive call centre-based approach that fails to meet the needs of patients and healthcare providers (HCPs) as consumers. Yet, the healthcare experience is antiquated. Technology is upending every aspect of our lives, from retail to transportation.

Biopharma 89

Biopharma Patients Prescription Medical 89

Impetus Digital

OCTOBER 20, 2022

Based on over a decade of feedback from thousands of healthcare provider (HCP) advisors, across all therapeutic areas, we are consistently hearing that asynchronous virtual touchpoints (AVTs) on the Impetus InSite Platform® are the #1 preferred way of engaging with Big Pharma. About Impetus Digital.

Healthcare Provider 84

Healthcare Provider Transportation Pharma Healthcare 84

Rep-Lite

MARCH 21, 2024

Healthcare professionals come in all forms: pharmaceutical sales reps, surgical sales reps, biotech sales reps, etc. Medical sales representatives are healthcare professionals who promote medical equipment, pharmaceuticals, or services to hospitals, clinics, and physicians. So how much do medical sales reps make?

Medical sales 52

Medical sales Medical sales reps Medical Sales 52

Clarify Health

DECEMBER 27, 2021

Kenneth Park, Senior Vice President and General Manager of Life Sciences, moderated a Reuters’ speaker series on the successful applications of precision insights to better understand patient cohorts, hyper-segment markets and healthcare providers (HCPs), and assess the cost of care.

Physicians 52

Physicians Patients Transportation Marketing 52

Clarify Health

OCTOBER 26, 2021

The solution delivers instant access to precision insights on patient cohorts, healthcare providers, and market intelligence, which draw upon data from over 300M patient lives, including de-identified government and commercial claims, clinical, prescription and dispensing, and SDoH data at the patient-level. 2] Figure 1.

Food and Drug Administration 52

Food and Drug Administration Recruitment Pharmaceutical manufacturing Medical 52

Nixon Gwilt Law

NOVEMBER 30, 2023

CMS defines SDOH as including, but not limited to, “food insecurity, transportation insecurity, housing insecurity, and unreliable access to public utilities, when they significantly limit the practitioner’s ability to diagnose or treat the problem(s).”

Physicians 52

Physicians Patients Management Training 52

Clarify Health

MAY 19, 2020

As healthcare providers (HCPs) are re-deployed to care for COVID-19 patients, many chronically-ill patients will have less frequent follow-up with their doctors. Beyond age and pre-existing medical conditions, what other characteristics put patients at risk?

Biopharma 52

Biopharma Physicians Marketing Prescription 52

pharmaphorum

JANUARY 4, 2023

The supply chain for allogeneic cell therapies doesn’t start with the patient – donor cells are collected and then transported to the manufacturer for modification and filling and finishing, before being shipped to a GMP-compliant storage facility where products are kept frozen for on-demand delivery.

Transportation 91

Transportation Manufacturing Patients Networking 91

Pharmaceutical Technology

FEBRUARY 20, 2023

This may lead to therapies and dosing regimes being less suitable for minority populations – and according to Hans Bunschoten, chief strategy officer at clinical research company Cerba Research, part of Cerba Healthcare, this is a major problem. What future developments are you most excited about being part of Cerba Research?

Healthcare 52

Healthcare Healthcare Medicine Biopharma 52